CClinicalTrials.gg
RecruitingNCT06287710FRENCH-PREMAUpdated Mar 1, 2024

Fluid Responsiveness Evaluation by a Non-invasive Method in Children, Extended to PREterm Infants - FRENCH-PREMA

An observational study in Premature Baby 26 to 32 Weeks and Premature Baby 33 to 36 Weeks, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 1 Minute to 5 Months. Per ClinicalTrials.gov, last updated 2024-03-01.

Sponsored by University Hospital, Bordeaux · Observational

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 8 months later.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
20
Ages
1 Minute to 5 Months
Sex
All
01

Study summary

In this study, the investigators aim to validate a non-invasive marker of fluid-responsiveness in preterm infants (term below 37 gestational week) with acute circulatory failure based on standardized abdominal compression. This would allow physicians to identify which patient could benefit from a fluid expansion, thus avoiding a potentially useless or even dangerous fluid expansion, leading to fluid overload. To this end, the investigators will evaluate the diagnostic accuracy (sensitivity and specificity) of stroke volume variation induced by standardized abdominal compression for the diagnosis of fluid responsiveness (based on the gold-standard test: significant increase in cardiac index after fluid expansion).

Read the detailed description

Fluid expansion is the cornerstone of acute circulatory failure treatment in children and preterm infants with acute circulatory failure. Although this therapy drastically reduced mortality, several studies in recent years have highlighted the adverse effects of excessive fluid expansion especially for preterm infants such as PDA, chronic lung disease and mortality. Currently, the search for indicators to predict fluid responsiveness is a major issue in neonatal intensive care. These indicators are based on Franck-Starling's law: if small changes in preload lead to an increase in cardiac output, then fluid responsiveness can be expected. However, in children, the only validated indicator (respiratory variability of peak aortic velocity) can only be used in the absence of any spontaneous respiratory movement, a rare situation in practice. Recently, two pediatric studies investigated a simple clinical test: hepatic or abdominal compression. This clinical maneuver, by increasing venous return via mobilization of the hepato-splanchnic reserve, induces a transient and reversible preload increase. The evaluation of the hemodynamic effects of this "endogenous fluid expansion" allowed, according to the authors, to accurately predict fluid responsiveness. However, several factors reduce the applicability of these results: the small number of studies on this subject, the smaller volume of fluid used than in clinical practice, and the population studied, composed almost exclusively of children in postoperative of cardiac surgery.

Thus, there is a need of reliable preloads markers to guide intravenous volume rescusitation in neonates.

In this study, the investigators will evaluate the diagnostic accuracy of abdominal compression for the diagnosis of fluid responsiveness in preterm infants (\<37WA) with acute circulatory failure, hospitalized in neonatal intensive care unit for a medical or a non-cardiac surgical condition, for whom a fluid expansion was prescribed by the physician in charge. The index test will be the stroke volume variation following a standardized abdominal compression (before fluid expansion). The gold standard test will be the variation of cardiac output between baseline and after fluid expansion, a variation > 15% defining fluid responsiveness.

In this non interventional study of diagnostic accuracy, patients will undergo an extra echocardiographic assessment, but no supplemental blood test or invasive parameters will be collected. Simple clinical parameters will be collected within 4 hours after the fluid expansion.

02

Conditions studied

  • Premature Baby 26 to 32 Weeks
  • Premature Baby 33 to 36 Weeks

Browse trials for

Keywords

  • Circulatory failure (shock)
  • volume expansion
  • echocardiography
  • Shock
  • goal-directed fluid management
  • preterm infants
03

In context

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's planned enrollment of 20 is below the median of 112 across 777 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

University Hospital, Bordeaux is the lead sponsor of 783 studies on the registry; 188 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Minute to 5 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

As this is a pilot study in a population of premature infants (term bellow 37 weeks of amenorrhea), the projected number of patients included will be 20, based on the department's active patient file, in order to have a minimum of 40 fluid expansion required for the study.

Inclusion criteria

  • Premature newborn under 37 weeks of amenorrhea hospitalized in neonatal intensive care
  • Prescription of a 10 to 20ml/kg fluid expansion (crystalloid, blood products or albumin) by the physician in charge, whose goal would be to increase cardiac output (based on clinical, biological and/or echographic criteria).

Exclusion criteria

Exclusion Criteria:

  • Acute cardiogenic pulmonary edema
  • Hemodynamic instability making the delay necessary for abdominal compression and ultrasonography dangerous for the patient
  • Non corrected congenital cardiopathy, or inferior to 15 days postoperative. Intra-abdominal hypertension or painful abdominal palpation
  • Abdominal surgery in the last 15 days
  • Supine position contraindicated or deleterious
  • No investigator available to assess ultrasonographic measures
  • Impairment of echocardiographic acoustic window or restless patient making ultrasonography impossible
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • study of diagnostic accuracy

    Patients included in this study would have received fluid expansion in all cases, as the prescription of 10 to 20ml/kg fluid expansion by the physician in charge is the main inclusion criterion.

    Procedure: Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).

Interventions

  • ProcedureNon interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).

    Study of diagnostic accuracy (non-interventional, prospective, monocentric). Fluid expansion will be delayed for a few minutes while our index test is performed. After fluid expansion, patient will undergo an echocardiographic assessment of response to fluid expansion (gold-standard test). This will allow to test the diagnostic performance of the index test for the "prediction" of fluid responsiveness. The index test is the ΔSVi-AC: indexed percentage of stroke volume variation between baseline and during a standardized abdominal compression. Stroke volume will be assessed by transthoracic echocardiography. Patient will undergo 3 echocardiographic assessment: At baseline (stroke volume, cardiac output, left ventricular ejection fraction), During a standardized abdominal compression (stroke volume),After the 10 to 20ml/kg fluid expansion prescribed by the physician in charge (cardiac output).

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of the index test (ΔSVi-AC) for the diagnosis of fluid responsiveness,

    Diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of the index test (ΔSVi-AC) for the diagnosis of fluid responsiveness, defined by an increase of cardiac output \> 15% after fluid expansion (ΔCO-FE \> 15%, gold-standard test) Index test (ΔSVi-AC) will be calculated as the difference between SV after abdominal compression and SV at baseline, divided by SV at baseline (%). SV will be measured by echocardiographic assessment. Gold-standard test (ΔCO-FE) will be calculated as the difference between CO after fluid expansion and CO at baseline, divided by CO at baseline (%). CO will be measured by echocardiographic assessment. value) of the index test (ΔSVi-AC) for the diagnosis of fluid responsiveness, defined by an increase of cardiac output \> 15% after fluid expansion (ΔCO-FE \> 15%, gold-standard test)

    Time frame: after abdominal compression, 30 minutes to 4 hours after baseline

Secondary outcomes

  1. Diagnostic accuracy of the SAV mean and the ΔPeak for the diagnosis of fluid responsiveness

    Diagnostic accuracy of the SAV mean and the ΔPeak for the diagnosis of fluid responsiveness, defined by an increase of cardiac output \> 15% after fluid expansion (ΔCO-FE \> 15%, gold-standard test) in preterm infants. Comparison of the diagnostic accuracy of these tests.

    Time frame: after abdominal compression, 30 minutes to 4 hours after baseline

07

Study locations

1 of 1 sites recruiting
  • Bordeaux Hospital University
    Bordeaux, 33076, France
    • Sophie CRAMAREGEAS, MD · Contact · 0557821269
    • sophie.cramaregeas@chu-bordeaux.fr · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06287710
Lead sponsor
University Hospital, Bordeaux
Responsible party
Sponsor
First posted
Mar 1, 2024
Start date
Jan 17, 2024
Primary completion
Nov 17, 2024 (estimated)
Completion
Apr 17, 2025 (estimated)
Last update
Mar 1, 2024

Study contacts

Sophie CRAMAREGEAS, MD
Contact
sophie.cramaregeas@chu-bordeaux.fr
0557821269
Géraldine ROBERT
Contact
geraldine.robert@chu-bordeaux.fr
055821500
Sophie CRAMAREGEAS
principal investigator · Bordeaux hospital University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion